Targets › SSTR5
23 programs from 23 companies in 54 trials: 27 Phase 2, 14 Phase 1, 9 Phase 3, 4 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. (UniProt, P35346)
Open in Phaseline: the race on SSTR5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Antwerp | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 4 | Gastroenteropancreatic Neuroendocrine Tumor | Apr 2029 |
| Helsinki University Central Hospital | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 4 | Pancreatic Fistula | Dec 2029 |
| HTA | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | NETS Ga68 Lu177 | Nov 2026 |
| ITM Solucin | 177Lu-edotreotide PRRT Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors | SSTR2, SSTR5 | Phase 3 | Neuroendocrine Tumors | Jun 2027 |
| Advanced Accelerator Applications | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) … | Oct 2027 |
| Debiopharm International | Debio 4126 somatostatin analog (somatostatin receptor agonist) | SSTR2, SSTR5 | Phase 3 | Acromegaly | Jun 2028 |
| Sinotau Pharmaceutical Group | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Tumors | Dec 2028 |
| SWOG Cancer Research Network | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 3 | Pancreatic Carcinoma | Apr 2029 |
| Washington University School of Medicine | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Neoplasm | Nov 2034 |
| The Netherlands Cancer Institute | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 177Lu-DOTATOC Somatostatin receptor-targeted radionuclide therapy with lutetium-177 | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Memorial Sloan Kettering Cancer Center | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Prolactin-Producing Pituitary Tumor | Feb 2027 |
| Antonio Fojo | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 2 | Paraganglioma | Mar 2027 |
| University of Alberta | 68Ga-HA-DOTATATE Somatostatin receptor (SSR) PET imaging tracer - gallium-68 labeled somatostatin analog | SSTR1, SSTR2, SSTR3, SSTR5 | Phase 2 | Neuroendocrine Tumors | Aug 2027 |
| Australasian Gastro-Intestinal Trials Group | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Sep 2027 |
| University Hospital Heidelberg | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Desmoplastic Small Round Cell Tumor | Oct 2027 |
| CSPC ZhongQi Pharmaceutical Technology | Octreotide Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head Cancer | Aug 2028 |
| RECORDATI GROUP | Pasireotide Diaspartate Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Post-Bariatric Hypoglycemia | – |
| University Hospital, Basel, Switzerland | 177Lu-DOTA-JR11 Radiolabeled somatostatin antagonist; 177Lu-emitting radiopharmaceutical targeting somatos | SSTR2, SSTR5 | Phase 1 | Meningioma | Dec 2026 |
| RayzeBio | RYZ401 Ac-225-based targeted alpha therapy for somatostatin receptor expression | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 1 | GEP-NET | Feb 2027 |
| Novartis | Lutetium Oxodotreotide Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Glioblastoma; Extensive Stage Small Cell Lung Cancer | May 2027 |
| National Health Research Institutes, Taiwan | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 1 | Neuroendocrine Tumors,Gastroenteropancreatic | Aug 2027 |
| Jason Winnick | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Hypoglycemia; Iatrogenic | May 2028 |
Neuroendocrine Tumors (13) Meningioma (3) Metastatic Pancreatic Neuroendocrine Tumor (3) Gastroenteropancreatic Neuroendocrine Tumor (2) Gastroenteropancreatic Neuroendocrine Tumors (2) Glioblastoma (1) Extensive Stage Small Cell Lung Cancer (1) Desmoplastic Small Round Cell Tumor (1) Neuroendocrine Neoplasm (1) Paraganglioma (1) Hypoglycemia; Iatrogenic (1) Pancreatic Fistula (1)
protein or peptide (8), small molecule (8), mixed (7)
ITM Solucin (1) Novartis (1) University Hospital, Antwerp (1) University Hospital Heidelberg (1) Washington University School of Medicine (1) Antonio Fojo (1) Sinotau Pharmaceutical Group (1) University Hospital, Basel, Switzerland (1) Jason Winnick (1) Helsinki University Central Hospital (1) University of Alberta (1) HTA (1) Memorial Sloan Kettering Cancer Center (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) Australasian Gastro-Intestinal Trials Group (1) SWOG Cancer Research Network (1) Advanced Accelerator Applications (1) CSPC ZhongQi Pharmaceutical Technology (1) RECORDATI GROUP (1) The Netherlands Cancer Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.